Zentalis Pharmaceuticals (ZNTL)

• Market cap: $267M
• 1 day: 6.53%
• 5 days: 2.74%
• 1 month: -12.38%
• 3 months: 36.36%
• 6 months: 167.86%
• Year to date: 173.72%
• 1 year: 156.85%
• 5 years: -93.31%
• 10 years: -83.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 106